Abstract:BACKGROUND AND AIM Capecitabine is an orally bioavailable prodrug that is converted to 5-fluorouracil through several enzymatic steps, the last of which is mediated by thymidine phosphorylase (TP). TP has been reported to be expressed at higher levels in cancer tissue compared with normal counterpart. The present study aimed at evaluating the potential relationship between TP expression and benefit from capecitabine in patients with metastatic breast cancer (BC). METHODS Immunohistochemistry for TP and other biological markers was carried out on paraffin-embedded cancer tissues of 61 patients with BC treated with at least three cycles of capecitabine as single agent for metastatic disease. All patients had received capecitabine 1000 mg/m(2) b.i.d. days 1-14 every 21 days. The following variables were analyzed as potential determinants of benefit from capecitabine: TP expression, estrogen receptor (ER) and progesterone receptor status, human epidermal growth factor receptor-2 (HER-2) status, MIB-1 expression, performance status at the beginning of capecitabine treatment, stage at diagnosis, grade, presence of visceral metastases at the beginning of capecitabine treatment, and previous chemotherapy. RESULTS Overall, median time to progression (TTP) was 6.5 months (range 1.4-33). On multivariate analysis, ER status [hazard ratio (HR) for progression = 0.31; 95% confidence interval (CI) = 0.15-0.64; P = 0.002], presence of visceral metastases at the beginning of capecitabine treatment (HR = 2.30; 95% CI = 1.21-4.39; P = 0.01), and capecitabine as first- or second-line treatment (HR = 2.28; 95% CI = 1.21-4.32; P = 0.01) independently predicted TTP. TP was highly expressed in 34 of 61 cases (55.7%). In the subgroup of patients with TP-expressing tumor, TTP was significantly longer in patients who received anthracyclines and taxanes before capecitabine (median TTP 7.5 versus 3.3 months, P = 0.01, log-rank test). Similarly, patients with a TP-positive tumor showed a longer TTP if they received taxanes before capecitabine than patients with TP-positive tumor who did not receive this treatment (7.3 versus 3.4 months, P = 0.03). CONCLUSIONS These data provide further evidence that TP expression in BC could represent a biomarker of sensitivity to capecitabine treatment. Prospective studies with translational approach are desirable to confirm the predictive and prognostic role of TP.

A New DC/DC Converter With Wide-Range ZVS and Reduced Circulating Current

Schizophrenia-like Psychosis and Gitelman Syndrome: a Case Report and Literature Review.

Adult classic Bartter syndrome: a case report with 5-year follow-up and literature review

Digenetic Inheritance of SLC12A3 and CLCNKB Genes in a Chinese Girl with Gitelman Syndrome

Ventricular arrhythmia and tachycardia-induced cardiomyopathy in Gitelman syndrome, hypokalaemia is not the only culpable

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.

A Chinese Girl with Bartter Syndrome Type III Due to a Novel Mutation And/or Single Nucleotide Polymorphisms (snps) in CLCNKB Gene

[A delicate balance: Gitelman syndrome and gestational diabetes. A case report]

Hypokalemia, Hypomagnesemia, Hypocalciuria, And Recurrent Tetany: Gitelman Syndrome In A Chinese Pedigree And Literature Review

Genetics of Magnesium Disorders

Simultaneous Homozygous Mutations in SLC12A3 and CLCNKB in an Inbred Chinese Pedigree

Banishing Bad Buckling

The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease

Clinical and genetic analysis of a case of Gitelman syndrome accompanied with Graves disease and adrenocortical adenoma: A case report

Calcium Unresponsive Hypocalcemic Tetany: Gitelman Syndrome with Hypocalcemia

A New Case Report of a CLCNKB Complex Heterozygous Mutation in Adult-Onset Type III Bartter Syndrome

Hyperkalemia in CKD: an overview of available therapeutic strategies

Descartes and psychosomatic medicine.

Gitelman syndrome and ectopic calcification in the retina and joints

Concurrent Gitelman Syndrome and Hyperthyroidism: Diagnostic Challenges in a 51-Year-Old Patient

Tardive dyskinesias from the major tranquilizers.